Press Releases

Press Releases

  • September 7, 2021
    Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
  • August 27, 2021
    Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
  • August 11, 2021
    Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
  • July 8, 2021
    Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021
  • July 1, 2021
    Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
  • June 24, 2021
    Aileron Therapeutics to be Added to the Russell Microcap® Index
  • May 19, 2021
    Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities
  • May 11, 2021
    Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
  • March 24, 2021
    Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
  • March 4, 2021
    Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference